title: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
abstract: OBJECTIVE
  To determine whether concomitant treatment with intravenous heparin affects coronary patency and outcome in patients treated with alteplase thrombolysis for acute myocardial infarction.
  
  
  METHODS
  Double blind randomised trial.
  Alteplase 100 mg (not weight adjusted) plus aspirin (250 mg intravenously followed by 75-125 mg on alternate days) plus heparin (5000 units intravenously followed by 1000 units hourly without dose adjustment) was compared with alteplase plus aspirin plus placebo for heparin.
  
  
  METHODS
  19 cardiac centres in six European countries.
  
  
  METHODS
  652 patients aged 21-70 years with clinical and electrocardiographic features of infarcting myocardium in whom thrombolytic therapy could be started within six hours of the onset of major symptoms.
  
  
  METHODS
  Angiographic coronary patency 48-120 hours after randomisation.
  
  
  RESULTS
  Coronary patency (TIMI grades 2 or 3) was 83.4% in the heparin group and 74.7% in the group given placebo for heparin. The relative risk of an occluded vessel in the heparin treated group was 0.66 (95% confidence interval 0.47 to 0.93). Mortality was the same in both groups. There were non-significant trends towards a smaller enzymatic infarct size and a higher incidence of bleeding complications in the group treated with heparin.
  
  
  CONCLUSIONS
  Concomitant intravenous heparin improves coronary patency in patients with alteplase. Whether this can be translated into improved clinical benefit needs to be to be tested in a larger trial.
authors.affiliation: Glenfield General Hospital, Leicester.
authors.forename: D P
authors.initials: DP
authors.lastname: de Bono
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
authors.forename: J
authors.initials: J
authors.lastname: Tijssen
authors.forename: A E
authors.initials: AE
authors.lastname: Arnold
authors.forename: A
authors.initials: A
authors.lastname: Betriu
authors.forename: C
authors.initials: C
authors.lastname: Burgersdijk
authors.forename: L
authors.initials: L
authors.lastname: López Bescos
authors.forename: E
authors.initials: E
authors.lastname: Mueller
authors.forename: M
authors.initials: M
authors.lastname: Pfisterer
authors.forename: F
authors.initials: F
authors.lastname: Van de Werf
mesh_terms: D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D012008:Recurrence; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014654:Vascular Patency
chemical_list: D006493:Heparin; D010959:Tissue Plasminogen Activator